Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 14.3%High 5 · 71.4%

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin leads to higher isolation of other micro‐organisms from the respiratory tract:… compared with oral ciprofloxacin (high certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 2.07
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous ceftazidime with tobramycin vs ciprofloxacin

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.78 [0.55, 1.1]
1 study · 285 participants
High

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.97
1 study · 285 participants
Moderate